Sign up to access all valuation multiples
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
1944
36.8K+
LTM Revenue $16.8B
LTM EBITDA $4.8B
$36.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Teva Pharmaceutical Indus has a last 12-month revenue (LTM) of $16.8B and a last 12-month EBITDA of $4.8B.
In the most recent fiscal year, Teva Pharmaceutical Indus achieved revenue of $16.5B and an EBITDA of $777M.
Teva Pharmaceutical Indus expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Teva Pharmaceutical Indus valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $16.8B | XXX | $16.5B | XXX | XXX | XXX |
| Gross Profit | $8.9B | XXX | $8.1B | XXX | XXX | XXX |
| Gross Margin | 53% | XXX | 49% | XXX | XXX | XXX |
| EBITDA | $4.8B | XXX | $777M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 5% | XXX | XXX | XXX |
| EBIT | $4.4B | XXX | $3.4B | XXX | XXX | XXX |
| EBIT Margin | 26% | XXX | 20% | XXX | XXX | XXX |
| Net Profit | $2.9B | XXX | -$1.6B | XXX | XXX | XXX |
| Net Margin | 18% | XXX | -10% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $14.5B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of September 5, 2025, Teva Pharmaceutical Indus's stock price is $19.
Teva Pharmaceutical Indus has current market cap of $21.2B, and EV of $36.6B.
See Teva Pharmaceutical Indus trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $36.6B | $21.2B | XXX | XXX | XXX | XXX | $2.54 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of September 5, 2025, Teva Pharmaceutical Indus has market cap of $21.2B and EV of $36.6B.
Teva Pharmaceutical Indus's trades at 2.2x EV/Revenue multiple, and 47.1x EV/EBITDA.
Equity research analysts estimate Teva Pharmaceutical Indus's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Teva Pharmaceutical Indus has a P/E ratio of 7.2x.
See valuation multiples for Teva Pharmaceutical Indus and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $21.2B | XXX | $21.2B | XXX | XXX | XXX |
| EV (current) | $36.6B | XXX | $36.6B | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 7.6x | XXX | 47.1x | XXX | XXX | XXX |
| EV/EBIT | 8.3x | XXX | 10.9x | XXX | XXX | XXX |
| EV/Gross Profit | 4.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 7.2x | XXX | -13.0x | XXX | XXX | XXX |
| EV/FCF | 16.0x | XXX | 48.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTeva Pharmaceutical Indus's last 12 month revenue growth is 1%
Teva Pharmaceutical Indus's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Teva Pharmaceutical Indus's rule of 40 is 11% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Teva Pharmaceutical Indus's rule of X is 31% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Teva Pharmaceutical Indus and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | 75% | XXX | XXX | XXX |
| Rule of 40 | 11% | XXX | 6% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 31% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Race Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Supriya Lifescience | XXX | XXX | XXX | XXX | XXX | XXX |
| Ascentage Pharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| ST Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Alpha Cognition | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Teva Pharmaceutical Indus acquired XXX companies to date.
Last acquisition by Teva Pharmaceutical Indus was XXXXXXXX, XXXXX XXXXX XXXXXX . Teva Pharmaceutical Indus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Teva Pharmaceutical Indus founded? | Teva Pharmaceutical Indus was founded in 1944. |
| Where is Teva Pharmaceutical Indus headquartered? | Teva Pharmaceutical Indus is headquartered in United States of America. |
| How many employees does Teva Pharmaceutical Indus have? | As of today, Teva Pharmaceutical Indus has 36.8K+ employees. |
| Who is the CEO of Teva Pharmaceutical Indus? | Teva Pharmaceutical Indus's CEO is Mr. Richard D. Francis. |
| Is Teva Pharmaceutical Indus publicy listed? | Yes, Teva Pharmaceutical Indus is a public company listed on NYS. |
| What is the stock symbol of Teva Pharmaceutical Indus? | Teva Pharmaceutical Indus trades under TEVA ticker. |
| When did Teva Pharmaceutical Indus go public? | Teva Pharmaceutical Indus went public in 1982. |
| Who are competitors of Teva Pharmaceutical Indus? | Similar companies to Teva Pharmaceutical Indus include e.g. Race Oncology, Supriya Lifescience, Ascentage Pharma Group, ST Pharm. |
| What is the current market cap of Teva Pharmaceutical Indus? | Teva Pharmaceutical Indus's current market cap is $21.2B |
| What is the current revenue of Teva Pharmaceutical Indus? | Teva Pharmaceutical Indus's last 12 months revenue is $16.8B. |
| What is the current revenue growth of Teva Pharmaceutical Indus? | Teva Pharmaceutical Indus revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Teva Pharmaceutical Indus? | Current revenue multiple of Teva Pharmaceutical Indus is 2.2x. |
| Is Teva Pharmaceutical Indus profitable? | Yes, Teva Pharmaceutical Indus is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Teva Pharmaceutical Indus? | Teva Pharmaceutical Indus's last 12 months EBITDA is $4.8B. |
| What is Teva Pharmaceutical Indus's EBITDA margin? | Teva Pharmaceutical Indus's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Teva Pharmaceutical Indus? | Current EBITDA multiple of Teva Pharmaceutical Indus is 7.6x. |
| What is the current FCF of Teva Pharmaceutical Indus? | Teva Pharmaceutical Indus's last 12 months FCF is $2.3B. |
| What is Teva Pharmaceutical Indus's FCF margin? | Teva Pharmaceutical Indus's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Teva Pharmaceutical Indus? | Current FCF multiple of Teva Pharmaceutical Indus is 16.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
